Physician profile
Sandra L Everett
NPI 1174634976
$2,442.34
in general payments reported to CMS, 2019-2025
14 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $181 · 2021: $208 · 2022: $485 · 2023: $244 · 2024: $560 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.92 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,701.06 | 2019-2025 | Clareon, Hydrus Microstent, Unity |
| Sun Pharmaceutical Industries INC. | $153.85 | 2019-2023 | Cequa, Xelpros |
| Mallinckrodt Enterprises LLC | $119.10 | 2019 | |
| Sight Sciences, INC. | $101.83 | 2024 | Omni Surgical System |
| Merck Sharp & Dohme LLC | $81.52 | 2020-2025 | Bridion |
| Novartis Pharmaceuticals Corporation | $60.17 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $53.98 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $39.90 | 2023 | Vyzulta, Miebo |
| Aerie Pharmaceuticals, INC. | $29.72 | 2019 | |
| Horizon Therapeutics Plc | $26.65 | 2019-2022 | |
| Abbvie INC. | $23.68 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.06 | 2019 | |
| Convatec INC. | $17.16 | 2023 | |
| Shire North American Group INC | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.